Isothiocyanates such as sulforaphane [SF; (-)-1-isothiocyanato-(4R)-methylsulfinylbutane] have been shown to reduce prostate tumour growth and pulmonary metastasis in the TRAMP mouse model of prostate cancer [3,4], and to reduce the growth of prostate cancer xenografts in immune-deficient mice derived from the PTEN-deficient PC3 metastatic cell line [5]. This evidence concerns the gene PTEN and prostate cancer.